NCT06120075 - A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 19, 2024

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2026

Conditions

Advanced Cancer

Interventions

DRUG

AB801

Administered as specified in the treatment arm

DRUG

Docetaxel

Administered as specified in the treatment arm

Trial Locations (10)

10128

RECRUITING

Icahn School of Medicine at Mount Sinai/ The Tisch Cancer Center, New York

19104

RECRUITING

University Of Pennsylvania, Abramson Cancer Center, Philadelphia

20007

RECRUITING

Georgetown, Washington D.C.

22031

RECRUITING

Next Oncology Virginia, Fairfax

30322

RECRUITING

Emory University, Atlanta

49546

RECRUITING

START Midwest, Grand Rapids

75230

RECRUITING

Mary Crowley, Dallas

78229

RECRUITING

START - South Texas Accelerated Research Therapeutics, LLC., San Antonio

80218

RECRUITING

Sarah Cannon Research Institute, Denver

84119

RECRUITING

START Mountain Region, West Valley City